These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Efficacy and safety of haploidentical hematopoietic stem cell transplantation for 17 patients with paroxysmal nocturnal hemamoglobinuria]. Xia J; Chen SN; Chen J; Fan Y; Chen F; Ma X; Miao M; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2018 Nov; 39(11):904-907. PubMed ID: 30486585 [No Abstract] [Full Text] [Related]
24. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation. Seidel MG; Fritsch G; Matthes-Martin S; Lawitschka A; Lion T; Pötschger U; Rosenmayr A; Fischer G; Gadner H; Peters C Haematologica; 2005 Oct; 90(10):1405-14. PubMed ID: 16219578 [TBL] [Abstract][Full Text] [Related]
25. Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment. DeZern AE; Jones RJ; Brodsky RA Biol Blood Marrow Transplant; 2018 Dec; 24(12):e26-e30. PubMed ID: 30055352 [TBL] [Abstract][Full Text] [Related]
26. Single-Center Experience of Unrelated and Haploidentical Stem Cell Transplantation with TCRαβ and CD19 Depletion in Children with Primary Immunodeficiency Syndromes. Balashov D; Shcherbina A; Maschan M; Trakhtman P; Skvortsova Y; Shelikhova L; Laberko A; Livshits A; Novichkova G; Maschan A Biol Blood Marrow Transplant; 2015 Nov; 21(11):1955-62. PubMed ID: 26187864 [TBL] [Abstract][Full Text] [Related]
28. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944 [TBL] [Abstract][Full Text] [Related]
30. Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones. Mei M; Gupta R; O'Donnell M; Al Malki MM; Aldoss I; Ali H; Farol L; Snyder D; Forman SJ; Nakamura R; Khaled S Biol Blood Marrow Transplant; 2019 May; 25(5):e183-e185. PubMed ID: 30708188 [TBL] [Abstract][Full Text] [Related]
31. Reduced-intensity stem cell allografting for PNH patients in the eculizumab era: The Mexican experience. Schcolnik-Cabrera A; Labastida-Mercado N; Galindo-Becerra LS; Gomez-Almaguer D; Herrera-Rojas MA; Ruiz-Delgado GJ; Ruiz-Arguelles GJ Hematology; 2015 Jun; 20(5):263-6. PubMed ID: 25148373 [TBL] [Abstract][Full Text] [Related]
32. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis. Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451 [TBL] [Abstract][Full Text] [Related]
33. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience. Rzepecki P; Sarosiek T; Szczylik C Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840 [TBL] [Abstract][Full Text] [Related]
34. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Bethge WA; Haegele M; Faul C; Lang P; Schumm M; Bornhauser M; Handgretinger R; Kanz L Exp Hematol; 2006 Dec; 34(12):1746-52. PubMed ID: 17157172 [TBL] [Abstract][Full Text] [Related]
35. Horse anti-thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or no-go? Alashkar F; Dührsen U; Röth A Eur J Haematol; 2016 Oct; 97(4):403-5. PubMed ID: 26990688 [TBL] [Abstract][Full Text] [Related]
36. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857 [TBL] [Abstract][Full Text] [Related]
37. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040 [TBL] [Abstract][Full Text] [Related]
38. [The clinical characteristics of adult hemophagocytic lymphohistiocytosis treated with haploidentical donor hematopoietic stem cell transplantation]. Fu L; Wei N; Wang JS; Wu L; Wang YN; Huang DY; Liu JL; Wang Z Zhonghua Nei Ke Za Zhi; 2017 Apr; 56(4):273-278. PubMed ID: 28355720 [No Abstract] [Full Text] [Related]
39. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. Strober S Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036 [TBL] [Abstract][Full Text] [Related]
40. [Fludarabine-based increased-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia]. Sun C; Lin X; Huang Y; Song C; Tao Y; Tu S; Fang J; Chen T; Sun C; Wu B Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):221-4. PubMed ID: 24666488 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]